CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies
Revisit the OncLive On Air Episodes From February 2024
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies
Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
